Chantix is an anti-smoking drug owned by Pf Prism Cv. The drug's active ingredient is varenicline tartrate. Chantix first received its market authorization on May 10, 2006. The drug has 4 patents, of which 4 have already expired.
The Chantix generic is expected to be available after February 3, 2023. The last patent of Chantix (US7265119*PED) is set to expire on this date. However, the exact availability of the Chantix generic would be subject to other factors such as possible Para IV filings.
Chantix is primarily used as an aid to smoking cessation. The effectiveness of Chantix is due to its active ingredient, varenicline tartrate, which works by blocking the pleasurable effects of nicotine on the brain, thereby reducing the desire to smoke.
Chantix holds a total of 4 drug patents, all of which have already expired. The last significant patent affecting the generic release date of Chantix is 'US7265119*PED', which is set to expire on February 3, 2023. Below are the details of the patent: